T

op of the morning to you, and what a fine one it is. A warm and shiny sun is enveloping the Pharmalot campus this morning, where one of the short people has long since departed for the local schoolhouse and another short person is lingering for a holiday break. As for us, well, there is much to be done, which brings us to the list of tidbits below. All of which is to say the time has come for another cup of stimulation. Feel free to join us. And now, onward …

The Food and Drug Administration will add insulin to its campaign to increase competition, Bloomberg News explains. The FDA will add insulin products to a list of drugs that have lost their monopoly protections but that still lack a cheap generic version in order to highlight opportunities for generic makers. The agency has already indicated it will expedite review of any application for a product on the list.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy